Pfizer Inc PFE
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Pfizer Inc is a large-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $158.5B, based in the USA.
It employs about 75,000 people and has been listed since Jun 22, 1942.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Cheap or expensive? relatively cheap
The company is loss-making, so it has no P/E — we compare on price-to-sales instead.
Its price-to-sales (P/S) is 2.5 versus 5.8 for 4 direct peers — relatively cheap.
Revenue is growing 3% versus the same quarter last year.
The average analyst price target is 28.91, 4% above the current price (their view, not ours).
The stock sits at 79% of its one-year range (0% = the low, 100% = the high).
The risks
- • The company is loss-making.
Strengths
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Most analysts rate it buy (10 vs 2).
- ✅ Pays a dividend (6.1% a year).
What changed this week
Over the past week the stock fell 3.0% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot seekingalpha.com · 2026-10-03
- 3 AI Healthcare Stocks With Earnings Growth Up To 15% finance.yahoo.com · 2026-10-02
- Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo finance.yahoo.com · 2026-10-02
- Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know finance.yahoo.com · 2026-10-01
- Sector Update: Healthcare Stocks Fall Late Afternoon finance.yahoo.com · 2026-10-01
- Pfizer Says Eczema Drug Shows Significant Skin Clearance finance.yahoo.com · 2026-10-01
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.